Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
Innate Pharma (Nasdaq: IPHA) announced that an abstract for IPH4502, their novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for presentation at the AACR Annual Meeting 2025 in Chicago.
IPH4502 is currently in Phase 1 clinical trials for advanced solid tumors. The drug has shown preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin, as well as in tumors with low to moderate Nectin-4 expression, suggesting potential applications beyond urothelial carcinoma.
The presentation will take place during a poster session on Tuesday, April 29, 2025. Additionally, CEO Jonathan Dickinson will present an update on Innate's pipeline and strategy at the AACR Oncology Industry Partnering Event on April 24, 2025.
Innate Pharma (Nasdaq: IPHA) ha annunciato che un abstract per IPH4502, il loro nuovo inibitore della topoisomerasi I in forma di Antibody Drug Conjugate (ADC) mirato a Nectin-4, è stato selezionato per essere presentato al AACR Annual Meeting 2025 a Chicago.
IPH4502 è attualmente in fase 1 di sperimentazione clinica per tumori solidi avanzati. Il farmaco ha mostrato efficacia antitumorale preclinica in modelli di resistenza primaria e acquisita a enfortumab vedotin, così come in tumori con espressione di Nectin-4 bassa o moderata, suggerendo potenziali applicazioni oltre il carcinoma uroteliale.
La presentazione avrà luogo durante una sessione di poster il martedì 29 aprile 2025. Inoltre, il CEO Jonathan Dickinson presenterà un aggiornamento sul pipeline e sulla strategia di Innate durante l'AACR Oncology Industry Partnering Event il 24 aprile 2025.
Innate Pharma (Nasdaq: IPHA) anunció que se ha seleccionado un resumen para IPH4502, su nuevo inhibidor de la topoisomerasa I en forma de Antibody Drug Conjugate (ADC) dirigido a Nectin-4, para su presentación en el AACR Annual Meeting 2025 en Chicago.
IPH4502 se encuentra actualmente en ensayos clínicos de fase 1 para tumores sólidos avanzados. El fármaco ha mostrado eficacia antitumoral preclínica en modelos de resistencia primaria y adquirida a enfortumab vedotin, así como en tumores con expresión de Nectin-4 baja a moderada, lo que sugiere aplicaciones potenciales más allá del carcinoma urotelial.
La presentación tendrá lugar durante una sesión de carteles el martes 29 de abril de 2025. Además, el CEO Jonathan Dickinson presentará una actualización sobre la cartera y la estrategia de Innate en el AACR Oncology Industry Partnering Event el 24 de abril de 2025.
Innate Pharma (Nasdaq: IPHA)는 그들의 새로운 톱이소머라제 I 억제제 항체 약물 접합체 (ADC)인 IPH4502의 초록이 시카고에서 열리는 AACR 연례 회의 2025에서 발표될 것이라고 발표했습니다.
IPH4502는 현재 1상 임상 시험에 있으며, 고급 고형 종양에 대한 것입니다. 이 약물은 엔포르투맙 베도틴에 대한 1차 및 후천적 저항성 모델에서 전임상 항종양 효능을 보였으며, Nectin-4 발현이 낮거나 중간인 종양에서도 효과를 나타내어 요로상피암을 넘어선 잠재적인 응용 가능성을 시사합니다.
발표는 2025년 4월 29일 화요일 포스터 세션 중에 진행됩니다. 또한, CEO인 Jonathan Dickinson은 2025년 4월 24일 AACR Oncology Industry Partnering Event에서 Innate의 파이프라인 및 전략에 대한 업데이트를 발표할 것입니다.
Innate Pharma (Nasdaq: IPHA) a annoncé qu'un résumé pour IPH4502, leur nouvel inhibiteur de la topoisomérase I sous forme d'Antibody Drug Conjugate (ADC) ciblant Nectin-4, a été sélectionné pour être présenté lors de la AACR Annual Meeting 2025 à Chicago.
IPH4502 est actuellement en essais cliniques de phase 1 pour des tumeurs solides avancées. Le médicament a montré une efficacité antitumorale préclinique dans des modèles de résistance primaire et acquise à l'enfortumab vedotin, ainsi que dans des tumeurs avec une expression de Nectin-4 faible à modérée, suggérant des applications potentielles au-delà du carcinome urotélial.
La présentation aura lieu lors d'une session d'affiches le mardi 29 avril 2025. De plus, le PDG Jonathan Dickinson présentera une mise à jour sur le pipeline et la stratégie d'Innate lors de l'AACR Oncology Industry Partnering Event le 24 avril 2025.
Innate Pharma (Nasdaq: IPHA) gab bekannt, dass ein Abstract für IPH4502, ihren neuartigen Topoisomerase-I-Hemmer Antibody Drug Conjugate (ADC), das auf Nectin-4 abzielt, für die Präsentation auf dem AACR Annual Meeting 2025 in Chicago ausgewählt wurde.
IPH4502 befindet sich derzeit in Phase-1-Studien für fortgeschrittene solide Tumoren. Das Medikament hat in präklinischen Modellen von primärer und erworbener Resistenz gegen Enfortumab Vedotin sowie in Tumoren mit niedriger bis moderater Nectin-4-Expression antitumorale Wirksamkeit gezeigt, was auf potenzielle Anwendungen über das Urothelkarzinom hinaus hindeutet.
Die Präsentation findet während einer Postersession am Dienstag, den 29. April 2025 statt. Darüber hinaus wird CEO Jonathan Dickinson am 24. April 2025 auf der AACR Oncology Industry Partnering Event ein Update zu Innates Pipeline und Strategie präsentieren.
- Drug shows efficacy in resistant tumors and broader application potential
- Successfully advanced to Phase 1 clinical trials
- Demonstrates effectiveness in low Nectin-4 expression tumors
- Still in early clinical development phase
- Efficacy data to preclinical studies
- IPH4502 is a novel and differentiated exatecan ADC targeting Nectin-4, currently investigated in a Phase 1 clinical trial in advanced solid tumors.
- IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors with low to moderate levels of Nectin-4 expression, extending its potential beyond urothelial carcinoma.
- Jonathan Dickinson, CEO of Innate, to present in a Showcase Session at the AACR Oncology Industry Partnering Event
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that an abstract regarding IPH4502, its novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) targeting Nectin-4, has been selected for the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30 in
In addition, Jonathan Dickinson, CEO of Innate Parma, will present in a showcase session at the AACR Oncology Industry Partnering Event, to give an update on Innate’s pipeline and strategy.
Presentation details
AACR 2025 ANNUAL MEETING
IPH4502, a differentiated Nectin-4 exatecan antibody-drug conjugate
Abstract Number: 5443
Session Type: Poster session
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibody-Based Cancer Therapeutics 3
Session Date/Time: Tuesday Apr 29, 2025 2:00 PM – 5:00 PM
More information can be found on the AACR website.
AACR ONCOLOGY INDUSTRY PARTNERING EVENT
Showcase Session 2 | W192
Presenter: Jonathan Dickinson, Chief Executive Officer
Date and Time: Thursday Apr 24, 2025 4:50 PM
Location: McCormick Place Convention Center West Building,
More information can be found on the AACR Oncology Industry Partnering Event website.
About IPH4502
IPH4502 is a novel and differentiated topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4, a cell adhesion molecule that is overexpressed in several types of solid tumors, such as urothelial carcinoma, breast cancer, non-small cell lung cancer or gastro-intestinal tract cancer.
IPH4502 is currently investigated in a Phase 1 trial in advanced solid tumors. The Phase 1 trial includes a dose escalation part 1 and a dose optimization part 2 and will assess the safety, tolerability, and preliminary efficacy of IPH4502 in different solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers. The study plans to enroll approximately 105 patients.
In preclinical models, IPH4502 demonstrates strong bystander killing effect, and efficient internalization, enabling a potent anti-tumor activity in models with various Nectin-4 expression levels. Additionally, IPH4502 shows efficacy in models resistant to MMAE-ADC. These results support its potential for development beyond UC and in cancer patients treated with MMAE-based ADCs.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).
Innate’s portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.
Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in
Learn more about Innate Pharma at www.innate-pharma.com. Follow us on LinkedIn and X.
Information about Innate Pharma shares
ISIN code
|
FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 |
Disclaimer on forward-looking information and risk factors
This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325985446/en/
For additional information, please contact:
Investors
Innate Pharma
Henry Wheeler
Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media Relations
NewCap
Arthur Rouillé
Tel.: +33 (0)1 44 71 00 15
innate@newcap.eu
Source: Innate Pharma SA
FAQ
What is IPH4502 and how does it differ from existing treatments?
What stage of development is IPHA's IPH4502 currently in?
When will IPHA present the IPH4502 data at AACR 2025?
What types of cancers could potentially be treated with IPHA's IPH4502?
